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Introduction: Increasing evidences have demonstrated that activation of alternative complement pathway plays an
important role in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The
current study aimed to investigate the association of complement factor H (CFH), a key regulator of the alternative
complement pathway, with the disease activity of AAV.
Methods: Plasma CFH levels were measured in 82 patients with myeloperoxidase (MPO)-AAV in active stage. Of the
82 patients, plasma CFH levels of 27 patients were longitudinally measured. Serum anti-CFH autoantibodies were
screened in AAV patients. Circulating complement activation profiles including C4d, Bb, C3a, C5a and soluble C5b-9
of AAV patients in active stage were further detected. Associations between plasma CFH levels and clinicopathological
parameters as well as the prognosis were analyzed.
Results: Plasma CFH levels were significantly lower in active AAV patients compared with AAV patients in remission
and normal controls. Correlation analysis showed that plasma CFH levels inversely correlated with initial serum
creatinine, Birmingham Vasculitis Activity Score (BVAS), proportion of total crescents and cellular crescents in renal
specimens, and circulating levels of C3a, C5a and Sc5b-9, meanwhile positively correlated with estimated glomerular
filtration rate (eGFR), hemoglobin levels and circulating levels of C3. Moreover, multivariate survival analysis revealed
that plasma CFH levels were independently associated with composite outcome of death or end stage renal disease
(ESRD) in AAV patients, after adjusting for age, gender, hemoglobin level and urinary protein (P = 0.03, HR 0.85, 95 %
CI 0.73–0.98) or adjusting for age, gender, total crescents (%) and urinary protein (P = 0.03, HR 0.85, 95 % CI 0.73–0.98),
while not as an independent predictor after adjusting for age, gender, serum creatinine and urinary protein (P = 0.57,
HR 0.96, 95 % CI 0.83–1.11).
Conclusion: In conclusion, plasma CFH levels are associated with disease activity, and, to some extent, associated with
composite outcomes of patients with MPO-ANCA-associated vasculitis.Introduction
Anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a group of systemic autoimmune dis-
eases, characterized by pauci-immune necrotizing small-
vessel vasculitis and circulating autoantibodies against
neutrophil cytoplasmic constituents, especially proteinase
3 (PR3) and myeloperoxidase (MPO). AAV comprises* Correspondence: chenmin74@sina.com
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angiitis (MPA), eosinophilic granulomatosis with polyan-
giits (EGPA), and renal-limited vasculitis (RLV) [1].
The complement system, composed of more than 30
plasma-bound and membrane-bound proteins, plays a
central role in innate and humoral immunity, and can be
triggered for three different pathways: the classical path-
way, the lectin pathway, or the alternative pathway. Re-
cently, increasing evidence from both animal studies and
clinical studies has demonstrated that activation of alter-
native complement pathway plays a critical role in the
pathogenesis of AAV [2–8]. In particular, levels of Bb,
which reflect activation of the alternative pathway, inicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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with the disease activity of AAV [7, 8].
Actually, there are many soluble and membrane-bound
complement regulators protecting cells and tissues from
unintended injury by the complement cascade. Comple-
ment factor H (CFH), an abundant 155-kDa soluble glyco-
protein composed of 20 short consensus repeats (SCR), is
a key regulator of the alternative complement pathway in
the circulation and on cell surfaces. CFH competes with
factor B for binding to C3b, thus impeding formation of
alternative-pathway C3 convertases (C3bBb), accelerates
the decay of the alternative pathway C3-convertase
(C3bBb), and acts as a cofactor for the factor I-mediated
proteolytic inactivation of C3b [9]. The cofactor/decay ac-
celerating activity is mediated by SCR1–SCR4 in the N-
terminus, while SCR19 and SCR20 in the C-terminus are
essential for cell surface regulation of CFH [10]. In
addition, CFH contains specific binding sites for C-reactive
protein (CRP) [11]. Abnormalities of CFH resulting in dys-
regulation of the alternative complement pathway have
been involved in the pathogenesis of several autoimmune
diseases, including atypical hemolytic uremic syndrome
(aHUS) and C3 nephropathy [12, 13]. However, the associ-
ation of CFH and AAV is far from clear. In the current
study, we detected plasma levels of CFH in AAV patients
in both active stage and remission, and the associations be-
tween plasma CFH levels and clinicopathological charac-
teristics as well as prognosis were further analyzed.
Methods
Patients and blood samples
Eighty-seven patients with active AAV with complete clin-
ical and pathological data diagnosed in the Department of
Nephrology, Peking University First Hospital from 2007 to
2013 were initially enrolled in this study. However, five pa-
tients with PR3-ANCA-positive vasculitis were excluded
because increasing evidence suggests that MPO-AAV and
PR3-AAV are two distinct entities [14, 15]. Therefore, all
of the remaining 82 patients were positive for perinuclear
ANCA (P-ANCA) and MPO-ANCA at diagnosis. All
these patients met the criteria of the 2012 Chapel Hill
Consensus Conference definition for AAV [1]. Patients
with secondary vasculitis or with any other coexisting
renal disease, such as anti-glomerular basement mem-
brane nephritis, lupus nephritis, IgA nephropathy, diabetic
nephropathy, and membranous nephropathy, were ex-
cluded. Plasma samples from these patients were collected
on the day of renal biopsy and before the initiation of im-
munosuppressive therapy. Of the 82 patients with AAV,
plasma samples from 27 patients who achieved complete
remission defined as described previously [16] were also
collected at their regular ambulatory visits.
Plasma and serum samples of 65 age-matched and
gender-matched healthy blood donors and 30 patientswith renal biopsy-proven lupus nephritis in the active
stage were collected as normal controls and disease con-
trols, respectively. All patients with lupus nephritis fulfilled
the 1997 American College of Rheumatology revised cri-
teria for systemic lupus erythematosus (SLE) [17].
The blood samples of all participants were centrifuged
at 2000 × g for 15 minutes at 4 °C within 30 minutes
after collection. The plasma was then stored in aliquots
at −80 °C until use. Repeated freeze/thaw cycles were
avoided. Informed consent was obtained from each par-
ticipant. The research was in compliance with the Declar-
ation of Helsinki and was approved by the ethics
committees of Peking University First Hospital.
Clinical evaluation
The vasculitis disease activity was measured by the
Birmingham Vasculitis Activity Score (BVAS) [18]. Remis-
sion was defined as “absence of disease activity attributable
to active disease qualified by the need for ongoing stable
maintenance immunosuppressive therapy” (complete re-
mission), or “at least 50 % reduction of disease activity
score and absence of new manifestations” (partial remis-
sion), as described previously. Treatment resistance was
defined as unchanged or increased disease activity in pa-
tients with acute AAV after 4 weeks of treatment with
standard therapy or a reduction of <50 % in the disease ac-
tivity score after 6 weeks of treatment, or chronic persist-
ent disease defined as the presence of at least one major
item or three minor items on the disease activity score list
after >12 weeks of treatment [16].
The renal response to treatment, evaluated at 6 months
after initiation of immunosuppressive therapy, was judged
according to the following criteria, which were described
previously [19–21]: (1) complete recovery of renal func-
tion was indicated by normalization of renal function and
resolution of hematuria; (2) partial recovery of renal func-
tion was indicated by stabilization or improvement of
renal function, with serum creatinine ≥133 μmol/l but dia-
lysis independent; and (3) treatment failure was indicated
by progressive decline in kidney function with persistence
of active urinary sediment despite immunosuppressive
therapy.
The patients were followed up in outpatient clinics spe-
cified for AAV. The primary end point was defined as
death and the secondary end point was defined as end
stage renal disease (ESRD). The composite end point was
defined as death or ESRD.
Quantification of plasma CFH
The detection of plasma CFH was according to the
methods described previously [22, 23], with minor modi-
fication. In brief, serial concentrations of commercially
available highly purified human factor H from 1050 to
16.4 μg/ml were used to develop the standard curve.
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Curve expert 1.3 (Hyams DG, Starkville, MS, USA). The
linear portion of the standard curve was subsequently
used for the measurement of plasma CFH. All assays
were run in duplicate, and when standard errors were
over 10 %, samples were routinely re-analyzed.
Detection of serum anti-CFH autoantibodies using ELISA
Serum anti-CFH autoantibodies were detected by enzyme-
linked immunosorbent assay (ELISA), slightly modified as
described previously [24]. In brief, the 96-well plate was
coated with commercial highly purified human factor H in
4 μg/ml phosphate-buffered saline (PBS) or PBS alone as
antigen-free wells. After blocking with 1 % bovine serum
albumin (BSA), samples diluted 1:50 in PBS containing 0.1
% Tween-20 (PBST) were added to both antigen-coated
and antigen-free wells and followed by incubation with
alkaline phosphatase-conjugated goat anti-human IgG.
Color developed with substrate solution was measured
using an ELISA reader at 405 nm.
Quantification of circulating C3, C4d, Bb, C3a, C5a, and
soluble C5b-9 levels
Serum C3 was detected at the day of renal biopsy using a
rate nephelometry assay (IMMAGE, normal range >0.85 g/l;
Beckman-Coulter, Brea, California, USA). The measure-
ment of plasma concentrations of human complement
components, including complement fragments C4d, Bb,
C3a, C5a, and soluble C5b-9, were performed using com-
mercial ELISA kits according to the manufacturer’s in-
structions (Quidel, San Diego, CA, USA).
Renal histopathology
The renal biopsy specimens were routinely examined by
light microscopy, direct immunofluorescence, and elec-
tron microscopy. Biopsies were separately scored by two
pathologists blinded to the clinical data, according to the
previously standardized protocol for scoring renal biop-
sies of patients with AAV [25–27]. The presence of
glomerular lesions, including crescents (cellular/fibrous),
glomerulosclerosis (local/segmental/global), and fibrin-
oid necrosis, as well as a number of other lesions, were
calculated as the percentage of the total number of
glomeruli in a biopsy. Interstitial and tubular lesions
were scored semiquantitatively on the basis of the per-
centage of the tubulointerstitial compartment that was
affected: tubular atrophy (– for 0 %; + for 0–50 %, ++
for >50 %), interstitial infiltrates (– for 0 %, + for 0–20 %,
++ for 20–50 %, +++ for >50 %), and interstitial fibrosis
(– for 0 %, + for 0–50 %, ++ for >50 %).
Statistical analysis
Quantitative data were expressed as mean ± standard
deviation (for data that were normally distributed), ormedian and interquartile range (for data that were not
normally distributed). Comparison of normally distrib-
uted quantitative parameters between two groups was
assessed using the t test. In the case of multiple compar-
isons, one-way analysis of variance (ANOVA) followed
by Bonferroni multiple-comparison test was performed.
Comparison of normally distributed paired variables was
assessed using the paired-samples t test. Differences of
qualitative results were compared using the chi-square
test. Pearson’s test or Spearman’s test was used for cor-
relation analysis as appropriate. Kaplan–Meier curves
were performed to analyze the outcomes using the log-
rank test. All variables presented in Table 1 were
assessed using univariate survival analysis. If the P value
was <0.05, this predictor was allowed to be included in
multivariable Cox regression models. Age and sex were
forced into multivariable models, because they were po-
tential confounding factors according to previous studies
[28, 29]. Because of the close correlation between ini-
tial serum creatinine and hemoglobin (Hb) (rho =
0.56, P <0.001), initial serum creatinine and total crescents
(%) (rho = 0.55, P <0.001), these parameters were separ-
ately included in the multivariate analysis using Models A,
B and C. Results were expressed as hazard ratio (HR) with
95 % confidence interval (CI). Receiver operating charac-
teristic (ROC) curve analysis was performed to assess the
accuracy of plasma CFH level for distinguishing patients
with active disease from remission, and prognosis predic-
tion. The optimal cutoff values were constructed accord-
ing to the ROC curves. Analysis was performed with SPSS
statistical software package (SPSS11.0; SPSS Inc., Chicago,
IL, USA). Differences were considered significant if
P <0.05.
Results
Demographic and general data
Of the 82 patients with active AAV, 41 were male and 41
were female, with an age of 60.3 ± 13.0 (range 14–83)
years at diagnosis. The general data for these patients
are presented in Table 1.
Plasma CFH levels in patients and controls
Plasma CFH levels of patients with AAV in the active
stage and remission, patients with lupus nephritis, and
normal subjects are shown in Fig. 1a. Plasma levels of
CFH were significantly lower in patients with AAV in the
active stage compared with patients in remission and nor-
mal controls (417.87 ± 119.74 vs. 551.33 ± 114.12 μg/ml,
P <0.001; 417.87 ± 119.74 vs. 559.72 ± 87.92 μg/
ml, P <0.001, respectively). There was no significant
difference in the plasma CFH levels between AAV
patients in remission and normal controls (551.33 ±
114.12 vs. 559.72 ± 87.92 μg/ml, P >0.99). No sig-
nificant difference was observed in plasma levels of
Table 1 Clinical and histopathological parameters of patients
with active AAV
Parameter Value
Number of patients 82
Age (mean ± SD) 60.3 ± 13.0
Gender (male/female) 41/41
MPA/GPA 68/14
Initial serum creatinine (μmol/l) (median (IQR)) 321.0 (176.8, 637.3)
eGFR (ml/minute/1.73 m2)a (median (IQR)) 13.86 (6.51, 27.85)
Dialysis dependent at presentation 30 (36.6 %)
Urinary protein (g/24 hours) (mean ± SD) 1.95 ± 1.56
Skin rash 10 (12.2 %)
Arthralgia 26 (31.7 %)
Muscle pain 19 (23.2 %)
Pulmonary involvement 56 (68.3 %)
Ear, nose, and throat involvement 38 (46.3 %)
Ophthalmic involvement 16 (19.5 %)
Gastrointestinal involvement 17 (20.7 %)
Nervous system involvement 15 (18.3 %)
BVAS (mean ± SD) 21.1 ± 5.6
Hemoglobin (g/dl) (mean ± SD) 9.1 ± 1.9
ESR (mm/1 hour) (mean ± SD) 77.2 ± 39.9
Glomerular lesions (%)
Total crescents (mean ± SD) 54.1 ± 28.3
Cellular crescents (mean ± SD) 42.0 ± 26.7
Fibrous crescents (median (IQR)) 3.9 (0, 15.9)
Tubulointerstitial lesions
Tubular atrophy (−/+/++) 6/59/17
Interstitial infiltration (−/+/++/+++) 1/19/57/5
Interstitial fibrosis (−/+/++) 16/58/8
aeGFR (ml/minute per 1.73 m2) =175 × (plasma creatinine)−1.234 × age−0.179 ×
0.79 (if female) [30].
AAV anti-neutrophil cytoplasmic antibody-associated vasculitis, BVAS Birmingham
Vasculitis Activity Score, eGFR estimated glomerular filtration rate, ESR erythrocyte
sedimentation rate, GPA granulomatosis with polyangiitis, IQR interquartile range,
MPA microscopic polyangiitis, SD standard deviation
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patients (417.87 ± 119.74 vs. 418.06 ± 119.51 μg/ml,
P >0.99).
We then compared plasma levels of CFH in 27
AAV patients with plasma samples from both the ac-
tive stage and remission. The plasma levels of CFH
were significantly higher in remission than those in
the active stage (551.33 ± 114.12 vs. 431.72 ± 100.91
μg/ml, P <0.001) (Fig. 1b). Twenty-five of these 27
patients had an increase in plasma level of CFH in
remission compared with in the active stage, whereas
only two patients had a slight decrease in plasma
level of CFH in remission.Associations between plasma CFH levels and
clinicopathological parameters of patients with active
AAV
Associations between plasma CFH levels and clinico-
pathological parameters of patients with active AAV are
shown in Fig. 2. Correlation analysis showed that plasma
CFH levels inversely correlated with initial serum cre-
atinine and BVAS (rho = −0.42, P <0.001; r = −0.34, P =
0.002, respectively), and positively correlated with esti-
mated glomerular filtration rate (eGFR) [30] and Hb
level (rho = 0.43, P <0.001; r = 0.43, P <0.001, respect-
ively). For renal pathological parameters, plasma CFH
levels inversely correlated with the proportion of total
crescents and cellular crescents in the renal specimen
(r = −0.33, P = 0.003; r = −0.37, P <0.001, respectively).
Associations between plasma CFH levels and circulating
C3, C4d, Bb, C3a, C5a, and soluble C5b-9 levels in patients
with active AAV
The circulating complement parameters of patients with
active AAV are presented in Table 2. We further found
that plasma CFH levels positively correlated with serum
levels of C3 (r = 0.49, P <0.001) and inversely correlated
with some complement activation fragments, including
C3a, C5a, and Sc5b-9 (rho = −0.33, P = 0.02; rho = −0.41,
P = 0.005; r = −0.57, P <0.001, respectively).
Association between plasma CFH levels and outcomes of
AAV patients
Of the 82 active AAV patients, resistance to induction
therapy occurred in seven patients (8.5 %). There was no
significant difference in plasma CFH levels between pa-
tients who were resistant to induction therapy and pa-
tients who achieved remission (complete or partial)
(380.31 ± 83.92 vs. 421.38 ± 122.38 μg/ml, P = 0.39).
However, as for renal response to treatment, 16 patients
(19.5 %) had renal treatment failure 6 months after the
initiation of immunosuppressive therapy, and plasma
CFH levels were found to be significantly lower in pa-
tients with renal treatment failure compared with those
achieving recovery of renal function (complete or partial)
(364.33 ± 119.17 vs. 430.85 ± 117.10 μg/ml, P = 0.04).
In our cohort, patients with AAV were followed up for
a median period of 29 (range 1–138) months. During
the follow-up, 24 patients died, 23 patients developed
ESRD, and 38 patients reached the composite end point.
To evaluate the association between plasma CFH levels
and patients’ prognosis, patients were divided into three
groups of equal size according to plasma CFH levels.
Kaplan–Meier survival analysis showed that there were
no significant difference in all-cause mortality among
these three groups (P = 0.78). However, plasma CFH
levels were found to be associated with renal survival
and composite outcome of death or ESRD among these
Fig. 1 Plasma levels of complement factor H (CFH) in different groups. a Plasma levels of CFH in anti-neutrophil cytoplasmic autoantibody-
associated vasculitis (AAV) patients in the active stage and in remission, patients with lupus nephritis (LN), and normal controls. b Changes of
plasma CFH levels in 27 AAV patients with sequential plasma samples
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patients within the first tertile of plasma CFH levels
(≤369.18 μg/ml) had the poorest renal outcome and
composite outcome.
In univariate survival analysis of renal prognosis in pa-
tients with AAV, we found that plasma CFH level was a
risk factor for renal outcome (P = 0.01, HR 0.79 (per
50 μg/ml increase), 95 % CI 0.67–0.95) and was alsoFig. 2 Plasma levels of complement factor H (CFH) correlated with a initial
c hemoglobin, d proportion of cellular crescentsassociated with composite outcome (P = 0.003, HR 0.81
(per 50 μg/ml increase), 95 % CI 0.71–0.93). Besides
plasma CFH level, other candidate parameters entered
into the multivariate analysis are presented in Table 3.
The plasma CFH level failed to be an independent risk
factor for ESRD in any of the multivariate models. How-
ever, since death acts as an early competing event for
subsequent ESRD and analysis might be influenced byserum creatinine, b Birmingham Vasculitis Activity Score (BVAS),
Table 2 Circulating complement profile of patients with active AAV
Value Reference value [7]
Serum C3 (mg/ml) (mean ± SD) 0.89 ± 0.27 >0.85
Plasma Bb (μg/ml) (median (IQR)) 1.17 (0.70, 1.86) 0.63 ± 0.26
Plasma C3a (ng/ml) (median (IQR)) 1872.10 (464.20, 2354.95) 100.87 ± 70.55
Plasma C5a (ng/ml) (median (IQR)) 32.77 (10.97, 72.66) 8.19 ± 5.44
Plasma Sc5b-9 (ng/ml) (mean ± SD) 894.71 ± 357.48 360.82 ± 164.51
AAV anti-neutrophil cytoplasmic antibody-associated vasculitis, IQR inter-quartile range, SD standard deviation
Fig. 3 Associations between plasma levels of CFH and prognosis of patients with AAV. a Associations with renal survival. b Associations with
composite outcomes (death or ESRD)
Chen et al. Arthritis Research & Therapy  (2015) 17:129 Page 6 of 9
Table 3 Multivariate analysis of composite outcome in patients with AAV
P value Hazard ratio 95 % confidence interval
Model A
Age 0.69 0.99 0.96–1.02
Gender (male vs. female) 0.32 1.44 0.71–2.91
Hemoglobin (≤9 g/dl vs. >9 g/dl) 0.31 1.47 0.70–3.11
Urinary protein (per g/24 hour) 0.02 1.29 1.05–1.58
Plasma CFH levels (per 50 μg/ml increase) 0.03 0.85 0.73–0.98
Model B
Age 0.72 0.99 0.96–1.03
Gender (male vs. female) 0.36 1.39 0.69–2.82
Total crescents (%) (>50 % vs. ≤50 %) 0.26 1.69 0.68–4.17
Urinary protein (per g/24 hour) 0.09 1.21 0.97–1.52
Plasma CFH levels (per 50 μg/ml increase) 0.03 0.85 0.73–0.98
Model C
Age 0.31 1.02 0.99–1.05
Gender (male vs. female) 0.75 1.12 0.55–2.29
Initial serum creatinine (per mg/dl) <0.001 1.24 1.12–1.36
Urinary protein (per g/24 hour) 0.002 1.34 1.12–1.62
Plasma CFH levels (per 50 μg/ml increase) 0.57 0.96 0.83–1.11
AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis, CFH complement factor H
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This analysis revealed that the plasma CFH level was still
an independent predictor for the composite endpoint
after adjusting for age, gender, Hb level, and urinary pro-
tein in Model A (P = 0.03, HR 0.85, 95 % CI 0.73–0.98)
or for age, gender, total crescents (%), and urinary pro-
tein in Model B (P = 0.03, HR 0.85, 95 % CI 0.73–0.98)
(Table 3), while the plasma CFH level was not an inde-
pendent predictor after adjusting for age, gender, serum
creatinine, and urinary protein in Model C (P = 0.57,
HR 0.96, 95 % CI 0.83–1.11).
The ROC curve analysis showed that the plasma level
of CFH could, to some extent, distinguish patients with
active AVV from remission (area under the curve (AUC)
0.79, 95 % CI 0.70–0.89, P < 0.001). At the cutoff value
of 441.74 μg/ml for CFH, the sensitivity was 61 % and
the specificity was 89 %. The ROC curve was also plot-
ted to verify the accuracy of CFH for composite out-
come prediction. The AUC was 0.68 (95 % CI 0.56–0.80,
P = 0.008). This value suggested an optimal cutoff of
434.57 μg/ml for plasma CFH, providing a sensitivity of
79 % and a specificity of 57 %.Detection of serum CFH autoantibodies in patients with
AAV
Serum autoantibodies against CFH could not be de-
tected in patients with AAV.Discussion
Recently, cumulating evidence has demonstrated that acti-
vation of the alternative complement pathway plays a crit-
ical role in the pathogenesis of AAV. As a key regulator of
the alternative complement pathway, abnormalities of
CFH have been associated with many autoimmune dis-
eases, including aHUS, C3 nephropathy, and SLE [12, 13,
23, 31]. Moreover, association of a novel CFH mutation
with severe crescentic and necrotizing glomerulonephritis
was reported [32]. However, the role of CFH in AAV is
still far from clear. To our best of knowledge, there is a
lack of studies on circulating CFH in patients with AAV.
In our present study, we found that plasma levels of
CFH were significantly lower in patients with AAV in
active stage compared with patients in remission and
normal controls. Further analysis showed that plasma
CFH levels inversely correlated with initial serum cre-
atinine, BVAS, and the proportion of total crescents and
cellular crescents in renal specimens, but positively cor-
related with eGFR and Hb. These results indicated that
plasma CFH levels could reflect both systemic and renal
disease activity in patients with AAV. Moreover, plasma
CFH levels were found to be associated with restoration of
renal function (complete or partial) and, to some extent,
associated with the composite outcome of AAV patients.
However, when initial serum creatinine was taken into ac-
count, it failed to be an independent risk factor, which
might be relevant to the close correlation between CFH
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by the sample size, the value of plasma CFH level as a pre-
dictor for patients’ outcomes needs further investigation.
Our present study found a close association between
CFH and renal damage in patients with MPO-ANCA-
positive vasculitis. Data from the MPO-AAV mouse
model have confirmed that the alternative complement
pathway is required for induction of necrotizing and
crescentic glomerulonephritis by anti-MPO IgG [2]. Our
previous study also found that circulating Bb was associ-
ated with the severity of renal injury in patients with
MPO-AAV [7, 8]. CFH is a key regulator that controls
the alternative complement activation at the level of C3
convertase. Our current study found that plasma CFH
levels inversely correlated with circulating levels of C3
split product, C3a, and further correlated with the final
common pathway activated products, C5a and Sc5b-9,
which may contribute to endothelium damage through
enhanced neutrophil activation or direct effects on
membranes resulting in cell lysis. However, as a retro-
spective and observational study, it is difficult to sort out
whether the decreased plasma CFH levels are related to
excessive consumption because of overactivation of
complement in patients with active AAV, or are an initial
factor predisposing patients to AAV susceptibility by in-
sufficiently regulating the activation of alternative com-
plement pathway. Previous findings of aHUS suggested
that some specific CFH gene mutations could lead to
quantitative CFH deficiency [12]. A genetic mechanism
is unlikely to be the case in AAV patients, however, since
plasma CFH levels were restored during disease remis-
sion compared with active disease. The exact mechanism
is of great interest for further study.
Because an overlap of plasma CFH levels between AAV
patients and normal controls occurred, we speculate that
the quantitative deficiency of plasma CFH may be one as-
pect. Previous studies have revealed that autoantibodies
against CFH and genetic variations resulted in dysfunction
of CFH were important mechanisms involved in the
pathogenesis of aHUS [12]. However, our current study
showed that serum autoantibodies against CFH could not
be detected in patients with AAV, so other underlying
mechanisms of CFH in AAV are worthy of further study.
Interestingly, our previous work found that MPO, which
can be released from ANCA-stimulated neutrophils, could
inhibit the binding between modified/monomeric C-
reactive protein (mCRP) and CFH, and thus might
inhibit the negative regulation of alternative complement
activation [33]. This work indicated another potential way
in which CFH may be involved in the development of AAV,
but the detailed mechanism needs further investigation.
In the current study, only patients with MPO-ANCA
were included, since previous experimental and clinical
studies that investigated the role of the complementsystem in the pathogenesis of AAV focused mainly on
MPO-ANCA-positive vasculitis [2–5, 7, 8]. Moreover,
Chinese patients with AAV are predominantly MPO-
ANCA-positive, as demonstrated by our previous studies
[34, 35]. Whether the same is true for PR3-ANCA-
positive vasculitis requires further investigation.
Conclusions
The current study found that plasma levels of CFH are as-
sociated with disease activity and, to some extent, associ-
ated with composite outcomes of patients with MPO-AAV.
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SLE: Systemic lupus erythematosus.
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